share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Drops By 10.0%

Defense World ·  09/19 15:41

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) was the recipient of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 3,140,000 shares, a drop of 10.0% from the August 15th total of 3,490,000 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 354,000 shares, the days-to-cover ratio is presently 8.9 days.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in ACRS. Point72 Hong Kong Ltd acquired a new stake in Aclaris Therapeutics during the 4th quarter worth approximately $26,000. Nisa Investment Advisors LLC acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $26,000. UBS Group AG boosted its position in Aclaris Therapeutics by 41.4% during the 2nd quarter. UBS Group AG now owns 2,406 shares of the biotechnology company's stock worth $34,000 after buying an additional 704 shares during the period. Cubist Systematic Strategies LLC boosted its position in Aclaris Therapeutics by 163.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,050 shares of the biotechnology company's stock worth $126,000 after buying an additional 5,621 shares during the period. Finally, Amalgamated Bank acquired a new position in shares of Aclaris Therapeutics in the 1st quarter worth approximately $143,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Get Aclaris Therapeutics alerts:

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Aclaris Therapeutics in a report on Monday, August 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $38.00.

Aclaris Therapeutics Trading Down 6.4 %

ACRS opened at $13.47 on Monday. The company's 50 day moving average is $16.12 and its 200-day moving average is $15.21. Aclaris Therapeutics has a 1-year low of $9.26 and a 1-year high of $19.97. The company has a market cap of $898.07 million, a P/E ratio of -10.05 and a beta of 0.59.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.05. Aclaris Therapeutics had a negative net margin of 1,355.98% and a negative return on equity of 40.14%. The company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $1.59 million. On average, equities analysts forecast that Aclaris Therapeutics will post -1.47 EPS for the current year.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Articles

  • Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
  • Kroger's is Your One-Stop Consumer Staples Stock
  • Adobe Perfects the Art of the Faceplant for Investors
  • Tax Credits are the Incentives in the Inflation Reduction Act
  • 3 Banks Worth Considering For Q4
  • Stock Market: 3 Islands Of Strength In A Sea Of Red

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.